Laura Pérez-Martínez-rekin lankidetzan egindako argitalpenak (12)

2021

  1. La investigación frente al SARS-COV-2 y la COVID-19 en el Departamento de Enfermedades Infecciosas del Hospital Universitario San Pedro-CIBIR

    Zubía, Núm. 39, pp. 63-73

2018

  1. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet

    Translational Research, Vol. 196, pp. 17-30

2017

  1. Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity

    Antiviral Therapy, Vol. 22, Núm. 2, pp. 163-168

2015

  1. Maraviroc modifica la composición de la microbiota intestinal en un modelo animal de obesidad: Una posible opción terapéutica para prevenir los trastornos metabólicos en pacientes infectados por el VIH

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 4, pp. 200-206

2014

  1. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910

2013

  1. Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

    PLoS ONE, Vol. 8, Núm. 1

  2. Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: A pilot study

    Journal of the International AIDS Society, Vol. 16

  3. Role of mitochondria in HIV infection and associated metabolic disorders: Focus on nonalcoholic fatty liver disease and lipodystrophy syndrome

    Oxidative Medicine and Cellular Longevity

2012

  1. Investigación en VIH y Lipodistrofia en el Hospital San Pedro-Cibir: modelos "in vitro" de adipocitos para el estudio de los efectos tóxicos de fármacos antirretrovirales

    Zubía, Núm. 24, pp. 129

  2. Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells

    Journal of Infection and Chemotherapy, Vol. 18, Núm. 4, pp. 485-493

2011

  1. Neutral actions of raltegravir on Adipogenesis, Glucose metabolism and lipolysis in 3T3-L1 Adipocytes

    Current HIV Research, Vol. 9, Núm. 3, pp. 174-179

2010

  1. Palpebral ptosis related to antiretroviral therapy: Report of two new cases and review of the literature

    HIV and AIDS Review, Vol. 9, Núm. 4, pp. 109-111